Specific in vitro and in vivo binding of 3H-raclopride a potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain
References (37)
- et al.
Life Sci.
(1978) - et al.
Eur. J. Pharmac.
(1981) - et al.
Life Sci.
(1984) - et al.
Life Sci.
(1981) - et al.
- et al.
Eur. J. Pharmac.
(1984) - et al.
Life Sci.
(1979) - et al.
Eur. J. Pharmac.
(1982) - et al.
Neurosci. Lett.
(1979) - et al.
Eur. J. Pharmac.
(1981)
Biochem. Pharmac.
(1978)
Eur. J. Pharmac.
(1978)
Nature, Lond.
(1979)
Br. J. Psychiat.
(1980)
Psychopharmacology
(1979)
Cited by (473)
Antagonism of D2 receptors via raclopride ameliorates amphetamine-induced associative learning deficits in male mice
2023, Behavioural Brain ResearchIn vitro characterization of [<sup>3</sup>H]VAT in cells, animal and human brain tissues for vesicular acetylcholine transporter
2021, European Journal of PharmacologyPharmacology profile of F17464, a dopamine D<inf>3</inf> receptor preferential antagonist
2021, European Journal of PharmacologyInvestigating the pathophysiology of anorexia nervosa using induced pluripotent stem cells: Background, current trends, and perspectives
2021, iPSCs for Modeling Central Nervous System Disorders, Volume 6Role of homeostatic feedback mechanisms in modulating methylphenidate actions on phasic dopamine signaling in the striatum of awake behaving rats
2019, Progress in NeurobiologyCitation Excerpt :The effect of the competitive D2 antagonist raclopride was modeled by a shift to the right of the activation curve, i.e.to a higher apparent EC50DA (Hall et al., 1988; Kohler et al., 1985). Raclopride binding, KdD2, was assumed to be 1.2 nM (Hall et al., 1988; Kohler et al., 1985; Lepiku et al., 1996). The concentration of raclopride used in vitro was 1.0 μM and the dose used in vivo was 0.3 mg/kg.
Copyright © 1985 Published by Elsevier Inc.